Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 12/20 | 0.40 |
| ▸ | NPY1R | P25929 | 7/20 | 0.40 |
| ▸ | CTSK | P43235 | 6/20 | 0.40 |
| ▸ | NPY2R | P49146 | 5/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.40 |
| ▸ | ANPEP | P15144 | 2/20 | 0.32 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.32 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16565958 | 0.91 | NPY4R (0.45) | NPY4RNPY1RCTSKNPY2RNPY5R | |
| SCHEMBL1394656 | 0.91 | NPY4R (0.45) | NPY4RNPY1RCTSKNPY2RNPY5R | |
| SCHEMBL16566054 | 0.91 | NPY4R (0.45) | NPY4RNPY1RCTSKNPY2RNPY5R | |
| SCHEMBL1394660 | 0.91 | NPY4R (0.45) | NPY4RNPY1RCTSKNPY2RNPY5R | |
| Hydrochloric Acid SCHEMBL11142131 | 0.90 | NPY4R (0.44) | NPY4RNPY1RCTSKNPY2RNPY5R | |
| SCHEMBL13724544 | 0.86 | NPY4R (0.52) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL1818349 | 0.86 | NPY4R (0.52) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL17866995 | 0.85 | NPY4R (0.41) | NPY4RNPY1RCTSKNPY2RNPY5R | |
| SCHEMBL17866998 | 0.85 | NPY4R (0.41) | NPY4RNPY1RCTSKNPY2RNPY5R | |
| SCHEMBL17866904 | 0.84 | NPY4R (0.40) | NPY4RNPY1RCTSKNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039531-A1 | Compositions, and kits comprising targeted aldehyde or acetal protease inhibitor compounds for treating muscle disorders | STRACHER ALFRED | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039531-A1 | Compositions, and kits comprising targeted aldehyde or acetal protease inhibitor compounds for treating muscle disorders | CPT1B, CAPNS1, CAPN1 | NPY4R 4822/4885NPY1R 4767/4885CTSK 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.